Lifecore's Alcon Loan Liability Doubles To $62.2 Million As The Buyout Reprices Its Biggest Customer's Debt
The proposed Webster Equity Partners deal pushed up the value of Alcon's early-repayment option and drove a $1.08-per-share quarterly loss.
Lifecore Biomedical's quarterly report carries a $62.2 million liability tied to the right of Alcon, its largest customer and its lender, to demand early repayment of its loan. The 10-Q, filed Wednesday, says the proposed buyout by Webster Equity Partners affiliates pushed the figure up from $30.9 million at the end of June, helping produce a third-quarter net loss of $40.1 million, or $1.08 per share.
How a buyout reprices a loan
Lifecore, a Chaska, Minnesota contract manufacturer that fills sterile injectable drugs and makes hyaluronic acid, carries its Alcon term loan with embedded early-prepayment options. Those options are marked to fair value each quarter. After the merger agreement was signed, management raised the probability of a change in control to 95% from 80% and moved the assumed timing to the end of 2026.
Of the $62.2 million, about $30.0 million is a change-in-control payment assumed at the end of 2026. The rest is the accounting cost of early repayment, driven by the gap between a 20.7% discount rate and the loan's 10% stated rate through its May 22, 2029 maturity.
The prior quarter's 10-Q carried the liability at $30.9 million. The change in fair value was a $31.3 million charge in the quarter, against $0.4 million a year earlier. The loan allows Alcon or Lifecore to require prepayment on a change in control at 115%, and $196.1 million of term loan principal is outstanding.
One counterparty, three roles
Alcon accounted for 52% of Lifecore's revenue for the nine months, holds the term loan, and has committed to provide part of the buyer's debt financing. The filing warns that any adverse change in that relationship could have a disproportionate effect on the business and the deal. Closing also hinges on an amendment to Alcon's manufacturing agreement, effective November 1, 2026, remaining in force, and since Alcon did not sign the merger agreement, neither side fully controls that condition.
Behind the charge, the business is shrinking. Nine-month revenue fell to $82.7 million from $105.7 million, and the operating loss was $3.0 million. Interest expense to Alcon is growing because much of the interest is paid in kind, which adds to principal.
Preferred holders force the clock
Holders of all 50,187 Series A preferred shares have demanded redemption on December 28, 2026. The company says internally generated cash is not expected to cover a significant part of it, and the merger agreement bars it from redeeming without the buyer's consent. The merger, if it closes, satisfies the obligation.
Under the deal, each common share converts into $6.28 in cash and one contingent value right. The company held $23.0 million in cash and $15.0 million of revolver availability at September 30. The merger agreement also prohibits it from raising debt or equity.
The antitrust waiting period lapses at 11:59 p.m. Eastern on November 9, 2026, barring early termination or an extension. Closing is targeted for the end of the fourth quarter.
Sources
- 10-Q Filing — Lifecore Biomedical (LFCR) — SEC EDGAR
- 10-Q Filing — Lifecore Biomedical (LFCR), Q2 FY2026 filed 2026-08-05 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, lfcr-2026q3xex991earningsr.htm) — Lifecore Biomedical, filed 2026-11-04 — SEC EDGAR